MZT2B

Across TCGA pan-cancer cohorts, MZT2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MZT2B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MZT2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MZT2B expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, LSCC, and PDAC are the cancer types where MZT2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	All	1.000	0.779	<.001	28	view →
LSCC	DFS	Quartile	All	0.511	0.790	.017	6	view →
PDAC	DFS	Median	III,IV	0.205	0.455	.022	6	view →
GBM	DFS	Median	All	0.815	0.658	.025	5	view →
CCRCC	OS	Median	All	1.000	0.848	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MZT2B–UCEC (DFS)

Open the UCEC breakdown →